

Volume 1 Issue 3 August 2019

## Prevalence and complication of Intrahepatic Cholestasis of Pregnancy

## Magda M Helmi\*

Private Consultant, Department of Obstetrician and Gynecologist, El hedaia Center, Giza, Egypt \*Corresponding Author: Magda M Helmi, Private Consultant, Department of Obstetrician and Gynecologist, El hedaia Center, Giza, Egypt. Received: May 20, 2019; Published: July 22, 2019

## Abstract

Intrahepatic cholestasis of pregnancy (ICP) is a temporary condition caused by maternal liver dysfunction during pregnancy. It is characterized by intense generalized pruritus (itchiness). It is a relatively rare condition affecting pregnant women. Though it has been reported to occur in as many as 4% of pregnancies in Chile, and in over 1% of pregnancies in Scandinavia, the rate of occurrence in the U.S. is believed to be less than 1 in 1,000 (0.1%). It appears to be genetically linked. Its prevalence in Egyptian pregnant population is not well defined. Therefore, detailed schematic investigation was carried out on 6900 pregnant cases until delivery of the baby. 79 patients showed high levels of bile acids and hepatic enzymes (20 cases with itching and 20 cases as control were reassessed for liver function test twice: at 30 and at 36 weeks and followed up to delivery). Highly significant correlation between high levels of bile acids, hepatic enzymes in blood and obstetric complications (preterm labor, operative delivery, fetal distress and lower than average apgar scoring).

Keywords: Intrahepatic Cholestasis; Pregnancy; Obstetric; Complications

## Introduction

Intrahepatic cholestasis of pregnancy (ICP) is a temporary condition caused by maternal liver dysfunction during pregnancy. To understand the link between ICP, bile acid levels and stillbirth [1], analysed more than 170,000 pregnancies from 40 international studies. The work was funded by ICP Support, Tommy's, Genesis Research Trust, Wellcome Trust and the NIHR. Severe Intrahepatic cholestasis of pregnancy is associated with adverse pregnancy outcome. Levels of BA correlate between mother and fetus [2]. This condition is characterized by intense generalized pruritus (itchiness) which usually begins in the third trimester. Though it may cause extreme discomfort, cholestasis of pregnancy is generally regarded as benign to the mother (Feldman M., *et al*). It has, however, been associated with an increased incidence of stillbirth [3-5].

The condition resolves shortly after delivery Intrahepatic cholestasis of pregnancy (ICP) is also known as obstetric cholestasis (OC) cholestatic jaundice of pregnancy, cholestatic hepatosis, and icterus gravidarum [3]. Cholestasis of pregnancy is a relatively rare condition affecting pregnant women. The rate of occurrence in Egypt is not accurately determined. The poCreams, such as aqueous cream with menthol, are safe to use in pregnancy and can provide some relief from itching.

There are some medications, such as ursodeoxycholic acid (UDCA), that help reduce bile acids and ease itching.

The purpose of the study is evaluating the incidence of obstetric cholestasis with pregnancy in Egyptian population/The danger from ICP is eliminated when the child is safely delivered. When cholestasis of pregnancy was first described, it was viewed as a benign condition. Since then, it has been widely established that ICP poses a significantly increased risk to the fetus.

Some specialists might advise earlier induction than this if the condition is severe (defined as bile acids over  $40\mu$ mol/L). Nevertheless, many physicians still perceive this condition as harmless

Citation: Magda M Helmi. "Prevalence and complication of Intrahepatic Cholestasis of Pregnancy". Acta Scientific Women's Health 1.3 (2019): 02-07.

and merely adopt a "watch and wait" policy. Because many obstetricians may see very few pregnancies with ICP in their careers, and most of those end without complication (even without treatment), they may be reluctant to induce labor when fetal monitoring shows no abnormalities. It is hoped, however, that they learn from the sad experience of other physicians who have published their data that the condition indeed poses serious risks and should be treated accordingly.

## Aim of the work

Evaluation of incidence of obstetric cholestasis in Egypt.

## **Methods and Material**

## Source of population

Health insurance unit in 6 October city (between years, 1995 - 2001), Antenatal clinic. There were no other obstetric services within this area at this time and therefore the great majority of pregnant women use the services of this obstetric unit.

#### **Selection of participants**

All of the participants 9600, were followed up during pregnancy. (They are all employed mid social class residence of Sixth October city). 79 out of 9600 pregnant women, complaining of pruritus (itching without a rash) with the current pregnancy.

All attendees were followed up included ordinary antenatal care up to delivery with regular antenatal laboratory profile and regular ultrasonic assessment of pregnancy. One biochemistry laboratory serves all of these health unit, We endeavored to trace all abnormal liver tests occurring in pregnant women in this geographical area using the computer database of the biochemistry laboratory. The principal biochemist flagged up all abnormal liver tests which originated from the antenatal clinic of our health unit.

#### **Exclusion criteria**

All patients were referred to internist in the same unit to be clinically laboratory and ultrasound assessed to exclude the following patient.

- 1. Any coincidental diseases.
- Any organic or infectious liver diseases, including viral hepatitis.
- 3. Any, dermatological condition.
- 4. Patients with hypertension and/or proteinuria.
- 5. Patients with acute fatty liver with pregnancy.
- 6. Twins and multiples.

The following laboratory tests (Pubmed-indexed for Medline) were done for 40 cases (20 cases with a history of itching, without a rash, and 20 cases without any complaint):

- Total bilirubin; Unconjugated bilirubin; Indirect bilirubin; Conjugated bilirubin; Direct bilirubin (Normal Values direct bilirubin: 0 to 0.3 mg/dl total bilirubin: 0.3 to 1.9 mg/ dl Note: mg/dl = milligrams per deciliter (Pub Med –indexed for Med line).
- ALT in serum SGPT; Serum glutamate pyruvate transaminase; Alanine transaminas. (Normal Values Normal range can vary according to a number of factors). This test is used to determine if a patient has liver damage (Pub Med –indexed for Med line).
- AST; Aspartate aminotransferase; Serum glutamic-oxaloacetic transaminase; SGOT; (Normal Values the normal range is 10 to 34 IU/L.m Note: IU/L = international units per liter (Pub Med –indexed for Med line).
- Bleeding time (Normal Values the bleeding stops within 1 to 9 minutes) this is a test that measures the speed at which small blood vessels close off to stop bleeding (the condition of the blood vessels) and platelet function (Pub Med –indexed for Med line).

Abnormal liver function tests (LFT) were defined as: bilirubin >25  $\mu$ mol/l; aspartate aminotransferase (AST) > 40 iu/l; gamma glutamyl transpeptidase ( $\gamma$ GT) >35 iu/l. It should be stressed that liver function was not assessed as routine in all pregnancies.

It should be stressed that liver function was not assessed as routine in all pregnancies.

Diagnostic criteria for obstetric cholestasis of pregnancy were based on clinical findings and investigations (Itching and elevated hepatic enzymes).

### Results

## **Prevalence of Cholestasis of pregnancy**

The prevalence of the condition in the chosen sample was (79 out of 6900) 1.14%.

Mild jaundice: occurred in only 2 pregnant cases with itching ('yellow' coloration of the skin, dark urine and pale faeces).

n%

Cases with itching 79 1.14 Cases without itching 6821 98.85 Total 6900 100

ControlBieding timeOutcome Total -n Normal-n% 0C-n%Bieding timePretern labor6Operative delivery1Fetal distressBIA Still birth40A Still birth15A Still birth100Meconium2.56894534710041734639273226810417346392732268104095541540997.0555409.98405405.9405.9405.9406.970.15.9405.9406.970.15.9406.970.15.9406.970.17.9407.986.970.17.98.16.970.17.98.17.98.17.98.17.98.17.98.17.98.17.98.17.99.18.14.17 0 40 10 397.99.117.99.117.99.117.99.117.99.117.99.129.91.13 0W 14 group 13.50 3.64 9.0816 2	Pregnancy outcome	AST
Outcome Frain Notimating Octage     Financial Stress       Operative delivery     1       Fetal distress     18       Still birth     40       Meconium     15       280     25       699     45       347     100       417     34       6     39       273     22       681     0       341     85       409     97.0       5     55       409     97.0       5     40       0.998     40       5.9     40       0.97     40       7.7     Ever function tests (36 Weeks pregnancy)       8     7       8     Attro 0 40 100 39       11     Astro 25 Astro 37 94 8 39       8     Attro 0 40 100 39       11     Astro 37 94 8 39       12     35%       13     Astro 0 40 100 39       14     97 0 0 5       5     100 0 0 100 39       14     <	Outcome Total n Normal nº/ OC nº/	Bleeding time
Freeminadou     -       Pertail adou     -       Pertail distress     18       A Stull birth     40       Meconium     15       280     2.5       689     45       347     100       417     34       6     39       273     22       681     0       341     85       409     7.0       5     5       44     0       9.98     40       5     40       0.970     5       4     0       9.98     40       5     4       0.077     40       7     5       8     Test n. Normal % n. Abnormal % Total       6     Total bilirubin 2 5.1 37 94.8 39       8     ALT o 0 40 100 39       1     Att 0 0 40 100 39       1     Att 0 40 100 39       1     Att 0 40 100 3218 0.720 0.00       1     Mechonic B 51 51 0.79 0.836 0.36149 0.816 20 0.096<	Destorm Johon	с
Operation terms y		1
Framework     Framework       Astil birth     40       Meconium     15       280     2.5       689     45       347     100       417     34       6     39       273     22       681     0       341     6       0     5       409     5.70       5     4       0     9.80       5     4       0.998     40       5.99     40       0.07     40       7.7     5       4     0       0.07     40       7.7     5       8     100       0.07     40       7.7     5       8     100 40 100 39       11     10 40 100 39       12     25 4.17 4.35 8.39       135%     Bleeding time 39 100 0 0 39       145     4.17 30 W 1st group 4.040 8.18 1.932 20 0.350       147 30 W 1st group 10.400 8.218 0.720 20	Fotol distross	18
A unitableProvide the set of t		40
Sectional	A Suil bil ui	15
2-0-69910034710041734639273226810341854097.0555409.98405.54005.54005.54005.54005.54005.54005.54005.54005.54005.54006.610007.710007.710008100061000710008100061000710008100061000910009.81000100039111000111000111000111000111000121000131000141000151000151000161000171000010000100001000010000100000100001000000010000001000000000000000000000000000000000000	290	2.5
347   100     417   34     6   39     273   22     681   0     341   85     409   97.0     5   55     4   0     9.98   40     5.9   40     0.07   40     0.07   40     0.07   40     0.07   40     7   5.13     6   70.15     7   40     0.07   40     7   40     0.07   40     7   5.137     8   70.137     8   70.137     9.98   70.137     8   70.137     9.97   40     0.07   40     7   5.137     8   71.137     9.98   ALT 0 04 100 39     1   AS 72 56.417 43.58 39     9.98   ALT 30 W 1st group 32.00 3.169 0.0132     9.96   ALT 30 W 1st group 3.240 0.0316 0.00.098	690	45
34     417     6   39     273   22     681   0     341   85     409   97.0     5   5     4   0     9.98   40     5.5   400     0.70   40     5.99   40     0.70   40     7.7 <b>Liver function tests (36 Weeks pregnancy)</b> 8   7     6   Tostal bilirubin 2.5.137.94.8.39     8   ALT 0.0.4010.039     1   1.0.0.39     1   0.417.00.4010.039     1   0.417.00.4010.039     1   0.417.00.4010.03.9     1   0.417.00.4010.03.9     1   0.417.00.4010.03.9     1   0.417.00.4010.03.21.80.720.20     689   ALT 30 W 1st group 30.640.08.16.20.0.098     40%   ALT 30 W 1st group 70.900.86.38.19.32.20.0.350     681   ALT 30 W 1st group 70.900.86.38.19.32.20.0.350     681   ALT 30 W 1st group 70.900.86.38.19.32.20.0.350     682   ALT 30 W 1st group 70.900.86.38.19.32.20.0.350	247	100
6   39     273   22     681   0     341   85     409   97.0     5   55     4   0     9.98   40     5.9   40     5.99   40     0.07   40     7   100     7   100     8   7     8   100     9.99   40     0.07   40     7   100     8   100     6   7     8   1000 39     1   1000 39     1   1000 39     1   1000 39     1   1000 39     1   1000 39     1   1000 39     1   1000 0 39     1   1000 0 39     1   1000 0 0 39     1   1000 0 0 39     1   1000 0 0 39     1   1000 0 0 39     1   1000 0 0 39     1   1000 0 0 39	417	34
273   22     681   0     341   85     409   97.0     5   55     4   0     9.98   40     5   40     5.99   40     0.07   40     7   1000000000000000000000000000000000000	6	39
273   a     681   0     341   85     409   97.0     5   55     4   0     9.98   40     5.99   40     0.077   40     7   Liver function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     8   ALT 30 W 20 0 0 39     40%   Xeriable Mean SD SE N P     5%   ALT 30 W 1st group 30.500 3.649 0.816 20 0.098     Apgar scoring>5   ALT 36 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.988   AST 30 W 1st group 23.50 8.159 1.825 20 <td>0</td> <td>22</td>	0	22
341   85     409   97.0     5   55     4   0     9.98   40     5.5   40     5.99   40     0.07   40     7   Liver function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   Total bilirubin 2 5.1 37 94.8 39     1   0 0 40 100 39     1   ALT 0 0 40 100 39     1   Stat 2 56.4 17 43.58 39     30%   Bleeding time 39 100 0 0 39     40%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350 <	691	0
3-14   97.0     409   97.0     5   55     4   0     9.98   40     5.99   40     0.007   40     7   40     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   Section 1 25.4 17 43.58 39     8   ALT 0 0 40 100 39     1   Section 1 25.4 17 43.58 39     8   ALT 0 0 40 100 39     1   Section 1 25.4 17 43.58 39     9%   Bleeding time 39 100 0 0 39     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Alger scoring>5   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 1st group 2.100 8.290 1.854 20 0.580     682   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 1st group 2.100 8.290 1.854 20 0.580     682   ALT 30 W 2nd group 73.667 9.387 2.213 18	241	85
5   5     5   0     9.98   40     5   40     5.99   40     0.07   40     7   Liver function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 40.400 3.218 0.720 20     681   ALT 30 W 2 nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2 nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2 nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2 nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2 nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2 nd group 73.667 9.387 2.213 18     9.98 8   AST 30 W 2 nd group 73.667 9.387 2.213 18     9.98 8   AST 30 W 1 st group	400	97.0
4   0     9.98   40     5   40     5.99   40     0.07   40     7   Liver function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     3%   Bleeding time 39 100 0 0 39     40%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 36 W 1st group 73.667 9.387 2.213 18     9.98 8   ALT 36 W 2nd group 70.900 8.638 1.932 20 0.350     40%   Variable Mean SD SE N P     40%   ALT 36 W 1st group 40.400 3.218 0.720 20     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST 30 W 1st group 2.100 8.290 1.854 20 0.580     40%   AST 30 W 1st group 2.100 8.290 1.854 20 0.580     40%   AST 30 W 1st group 2.100 8.290 1.854 20 0.580     417   AST 30 W 2nd group 70.307 1.723 20 0.117     73 6 W 1st group 2.3550 8.159 1.825 20   AST 30 W 2nd group 4.6350 7.707 1.723 20 0.117     7041	5	55
Pose     Pose       9.98     40       5.99     40       0.07     40       7     Liver function tests (36 Weeks pregnancy)       8     Test n. Normal % n. Abnormal % Total       6     Total bilirubin 2 5.1 37 94.8 39       8     ALT 0 0 40 100 39       1     AST 22 56.4 17 43.58 39       35%     Bleeding time 39 100 0 0 39       40%     ALT values       40%     Variable Mean SD SE N P       5%     ALT 30 W 1st group 3.550 3.649 0.816 20 0.098       ALT 30 W 2nd group 70.008 6.638 1.932 20 0.350       681     ALT 30 W 2nd group 73.667 9.387 2.213 18       9.98 8     AST values       40%     Variable Mean SD SE N P       40%     ALT 30 W 1st group 2.100 8.290 1.854 20 0.580       681     ALT 30 W 2nd group 73.667 9.387 2.213 18       9.98 8     AST values       40%     Variable Mean SD SE N P       AST 30 W 1st group 2.2100 8.290 1.854 20 0.580       40%     AST values       40%     AST values       40%     AST 30 W 1st group 2.2100 8.290 1.854 20 0.580       40%	4	0
5   40     5,99   40     0.07   40     7   Ever function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     30%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Algar scoring>5   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST 30 W 1st group 23.550 8.159 1.825 20     40%   Xartable Mean SD SE N P     AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 30 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 30 W 2nd group 50.944 9.879 2.328 18	+ 9 98	40
5.99   40     0.07   40     7   Liver function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     30%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Appar scoring>5   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Appar scoring>5   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Appar score at 5 min was satisfactory in all neonates.   AST 30 W 2nd group 70.900 8.638 1.932 20 0.350     Liver function tests (32 Weeks pregnancy)   AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 40.305 7.707 1.723 20 0.117     Total bilirubin   AST 30 W 2nd group 50.944 9.879 2.328 18	5.50	40
0.07   40     7   Liver function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST 30 W 1st group 22.100 8.290 1.854 20 0.580     40%   Ast 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 30 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18	5 99	40
7   Liver function tests (36 Weeks pregnancy)     8   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     30%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     682   ALT 30 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Apgar score at 5 min was satisfactory in all neonates.   AST 30 W 1st group 23.550 8.159 1.825 20     Apgar score at 5 min was satisfactory in all neonates.   AST 30 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18     ALT   AST 30 W 2nd group 50.944 9.879 2.328 18	0.07	40
AEnter infiction tests (50 weeks pregnancy)8Test n. Normal % n. Abnormal % Total6Total bilirubin 2 5.1 37 94.8 398ALT 0 0 40 100 391AST 22 56.4 17 43.58 3935%Bleeding time 39 100 0 0 3940%ALT values30%ALT values40%Variable Mean SD SE N P5%ALT 30 W 1st group 39.550 3.649 0.816 20 0.098Apgar scoring>5ALT 30 W 1st group 70.900 8.638 1.932 20 0.350681ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350681ALT 36 W 2nd group 73.667 9.387 2.213 189.98 8AST 30 W 2nd group 73.667 9.387 2.213 1840%AST 30 W 1st group 22.100 8.290 1.854 20 0.580Liver function tests (32 weeks pregnancy)AST 36 W 1st group 23.550 8.159 1.825 20Test r Normal % n. Abnormal % TotalAST 30 W 2nd group 46.350 7.707 1.723 20 0.117Total bilirubinAST 36 W 2nd group 50.944 9.879 2.328 18ALTAST 36 W 2nd group 50.944 9.879 2.328 18	7	Liver function tests (26 Weaks promoney)
6   Test n. Normal % n. Abnormal % Total     6   Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     30%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST values     40%   Variable Mean SD SE N P     ALT 30 W 2nd group 73.667 9.387 2.213 18   State score at 5 min was satisfactory in all neonates.     40%   AST values     40%   Variable Mean SD SE N P     AST 30 W 1st group 22.100 8.290 1.854 20 0.580   State score at 5 min was satisfactory in all neonates.     40%   Variable Mean SD SE N P     AST 30 W 1st group 23.500 8.159 1.825 20   State score at 5 min was satisfactory in all neonates.     Liver function tests (32 Weeks pregnancy)   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 30 W 2nd group 50.944 9.879 2.32	, 8	Liver function tests (56 weeks pregnancy)
7 Total bilirubin 2 5.1 37 94.8 39     8   ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     30%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST values     40%   Variable Mean SD SE N P     40%   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST values     40%   Variable Mean SD SE N P     AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 36 W 1st group 23.500 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18     ALT   AST 36 W 2nd group 50.944 9.879 2.328 18	6	Test n. Normal % n. Abnormal % Total
ALT 0 0 40 100 39     1   AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     30%   ALT values     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     689   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST 20 W 2nd group 73.667 9.387 2.213 18     40%   Variable Mean SD SE N P     ALT 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 30 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18     ALT   AST 30 W 2nd group 50.944 9.879 2.328 18	8	Total bilirubin 2 5.1 37 94.8 39
AST 22 56.4 17 43.58 39     35%   Bleeding time 39 100 0 0 39     40%   ALT values     30%   ALT values     40%   X1 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 30 W 1st group 70.900 8.638 1.932 20 0.350     681   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST values     40%   Variable Mean SD SE N P     Apgar score at 5 min was satisfactory in all neonates.   AST values     Apgar score at 5 min was satisfactory in all neonates.   Variable Mean SD SE N P     AST 30 W 1st group 22.100 8.290 1.854 20 0.580   AST 30 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 30 W 2nd group 50.944 9.879 2.328 18     ALT   AST 30 W 2nd group 50.944 9.879 2.328 18	1	ALT 0 0 40 100 39
Bleeding time 39 100 0 0 39       40%     ALT values       30%     ALT values       40%     Variable Mean SD SE N P       5%     ALT 30 W 1st group 39.550 3.649 0.816 20 0.098       Apgar scoring>5     ALT 30 W 1st group 40.400 3.218 0.720 20       689     ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350       681     ALT 36 W 2nd group 73.667 9.387 2.213 18       9.98 8     ALT 36 W 2nd group 73.667 9.387 2.213 18       40%     Variable Mean SD SE N P       Apgar score at 5 min was satisfactory in all neonates.     Variable Mean SD SE N P       AST 30 W 1st group 22.100 8.290 1.854 20 0.580     AST 30 W 1st group 23.550 8.159 1.825 20       Liver function tests (32 Weeks pregnancy)     AST 30 W 2nd group 46.350 7.707 1.723 20 0.117       Total bilirubin     AST 30 W 2nd group 50.944 9.879 2.328 18       ALT     Variable Mean SD SE N P	35%	AST 22 56.4 17 43.58 39
ALT values     30%   Variable Mean SD SE N P     40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 36 W 1st group 40.400 3.218 0.720 20     689   ALT 36 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   A S T values     40%   Astrable Mean SD SE N P     Apgar score at 5 min was satisfactory in all neonates.   Variable Mean SD SE N P     Apgar score at 5 min was satisfactory in all neonates.   AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 36 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     ALT 30 W 2nd group 50.944 9.879 2.328 18   ALT	40%	Bleeding time 39 100 0 0 39
40%   Variable Mean SD SE N P     5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 36 W 1st group 40.400 3.218 0.720 20     689   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST values     40%   Variable Mean SD SE N P     40%   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AST values     40%   Variable Mean SD SE N P     Apgar score at 5 min was satisfactory in all neonates.   Variable Mean SD SE N P     Ast 30 W 1st group 22.100 8.290 1.854 20 0.580   AST 30 W 1st group 23.550 8.159 1.825 20     Liver function tests (32 Weeks pregnancy)   AST 36 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18     ALT   St 36 W 2nd group 50.944 9.879 2.328 18	30%	ALT values
5%   ALT 30 W 1st group 39.550 3.649 0.816 20 0.098     Apgar scoring>5   ALT 36 W 1st group 40.400 3.218 0.720 20     689   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AS T values     40%   Variable Mean SD SE N P     Apgar score at 5 min was satisfactory in all neonates.   AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 36 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 50.944 9.879 2.328 18     ALT   AST 36 W 2nd group 50.944 9.879 2.328 18	40%	Variable Mean SD SE N P
Apgar scoring>5   ALT 36 W 1st group 40.400 3.218 0.720 20     689   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   AS T values     40%   Variable Mean SD SE N P     Apgar score at 5 min was satisfactory in all neonates.   AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 36 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 50.944 9.879 2.328 18     ALT   AST 36 W 2nd group 50.944 9.879 2.328 18	5%	ALT 30 W 1st group 39.550 3.649 0.816 20 0.098
ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     689   ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350     681   ALT 36 W 2nd group 73.667 9.387 2.213 18     9.98 8   A S T values     40%   Variable Mean SD SE N P     Astr 30 W 1st group 22.100 8.290 1.854 20 0.580   AST 30 W 1st group 23.550 8.159 1.825 20     Liver function tests (32 Weeks pregnancy)   AST 36 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18	Apgar scoring>5	ALT 36 W 1st group 40.400 3.218 0.720 20
681ALT 36 W 2nd group 73.667 9.387 2.213 189.98 8A S T values40%Variable Mean SD SE N PApgar score at 5 min was satisfactory in all neonates.AST 30 W 1st group 22.100 8.290 1.854 20 0.580Liver function tests (32 Weeks pregnancy)AST 36 W 1st group 23.550 8.159 1.825 20Test r Normal % n. Abnormal % TotalAST 30 W 2nd group 46.350 7.707 1.723 20 0.117Total bilirubinAST 36 W 2nd group 50.944 9.879 2.328 18ALTAST 36 W 2nd group 50.944 9.879 2.328 18	689	ALT 30 W 2nd group 70.900 8.638 1.932 20 0.350
9.98 8A S T values40%Variable Mean SD SE N PApgar score at 5 min was satisfactory in all neonates.Variable Mean SD SE N PLiver function tests (32 Weeks pregnancy)AST 30 W 1st group 22.100 8.290 1.854 20 0.580Liver function tests (32 Weeks pregnancy)AST 36 W 1st group 23.550 8.159 1.825 20Test r Normal % n. Abnormal % TotalAST 30 W 2nd group 46.350 7.707 1.723 20 0.117Total bilirubinAST 36 W 2nd group 50.944 9.879 2.328 18ALTAST 36 W 2nd group 50.944 9.879 2.328 18	681	ALT 36 W 2nd group 73.667 9.387 2.213 18
A S T values40%Apgar score at 5 min was satisfactory in all neonates.Liver function tests (32 Weeks pregnancy)Test r Normal % n. Abnormal % TotalTotal bilirubinAST 36 W 2nd group 50.944 9.879 2.328 18ALT	9.98.8	
Apgar score at 5 min was satisfactory in all neonates.Variable Mean SD SE N PAst 30 W 1st group 22.100 8.290 1.854 20 0.580Liver function tests (32 Weeks pregnancy)AST 36 W 1st group 23.550 8.159 1.825 20Test r Normal % n. Abnormal % TotalAST 30 W 2nd group 46.350 7.707 1.723 20 0.117Total bilirubinAST 36 W 2nd group 50.944 9.879 2.328 18ALT	40%	A S T values
Liver function tests (32 Weeks pregnancy)   AST 30 W 1st group 22.100 8.290 1.854 20 0.580     Liver function tests (32 Weeks pregnancy)   AST 36 W 1st group 23.550 8.159 1.825 20     Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18     ALT   ALT	Apgar score at 5 min was satisfactory in all neonates.	Variable Mean SD SE N P
Liver function tests (32 Weeks pregnancy)     AST 36 W 1st group 23.550 8.159 1.825 20       Test r Normal % n. Abnormal % Total     AST 30 W 2nd group 46.350 7.707 1.723 20 0.117       Total bilirubin     AST 36 W 2nd group 50.944 9.879 2.328 18       ALT     AST 36 W 2nd group 50.944 9.879 2.328 18		AST 30 W 1st group 22.100 8.290 1.854 20 0.580
Test r Normal % n. Abnormal % Total   AST 30 W 2nd group 46.350 7.707 1.723 20 0.117     Total bilirubin   AST 36 W 2nd group 50.944 9.879 2.328 18     ALT   ALT	Liver function tests (32 Weeks pregnancy)	AST 36 W 1st group 23.550 8.159 1.825 20
Total bilirubin     AST 36 W 2nd group 50.944 9.879 2.328 18       ALT     AST 36 W 2nd group 50.944 9.879 2.328 18	Test r Normal % n. Abnormal % Total	AST 30 W 2nd group 46.350 7.707 1.723 20 0.117
ALT	Total bilirubin	AST 36 W 2nd group 50.944 9.879 2.328 18
	ALT	

04

## Total bilirubin

Variable Mean SD SE N P BD 30 W 1<sup>st</sup> group 0.121 0.100 0.022 20 0.804 BD 36 W 1<sup>st</sup> group 0.129 0.103 0.023 20 BD 30 W 2<sup>nd</sup> group 0.238 0.214 0.048 20 0.221 BD 36 W 2<sup>nd</sup> group 0.329 0.244 0.056 19

### **Bleeding time**

Variable Mean SD SE N P BT 30 W 1st group 0.540 0.219 0.049 20 0.942 BT 36 W 1st group 0.535 0.216 0.048 20 BT 30 W 2nd group 0.885 0.669 0.150 20 0.976 BT 36 W 2nd group 0.879 0.563 0.129 19

Normal total bilirubin Values: 0.3 to 1.9 mg/dl. Abnormal total bilirubin Values: 2:6.8mg/dl.

Normal ALT Values: 35 to 45 IU/L. Abnormal ALT Values: 45:92 IU/L. Normal AST Values: 10 to 34 IU/L. Abnormal AST Values: 34:79 IU/L.

#### Discussion

The incidence of obstetric cholestasis in the sample examined were 1.14% Egyptian pregnant woman. It varies from 0.1% to 1.5% of pregnancies in Europe and 9.2%-15.6% in South American countries such as Bolivia or Chile [6]. It is particularly high in the native Araucanian population in Chile, where the proportion of affected pregnancies reaches nearly 28%. 3 and in over 1% of pregnancies in Scandinavia [7].

It appears to be genetically linked; more than one-third of patients have a family history of the disease e.g. mothers or sisters [5]. When the condition occurs in a pregnancy, it recurs in 60-70% of future pregnancies and occurs in every pregnancy of about 25% of affected women. However, the severity of ICP may vary from one pregnancy to the next and may skip pregnancies entirely.

The condition is also up to four times more common in twin or triplet pregnancies than in singleton pregnancies ICP has a mild association with previous miscarriage while it has been shown to have no association with obesity, infertility, maternal diabetes, or chronic illness [5].

## Itch

This is the most common and typical symptom. The itching associated with OC usually begins during the last ten weeks of pregnancy, although it can start much earlier. Women describe it as constant and sometimes as intolerable. The itch can be 'all over', but it is often worst on the hands and feet. Commonly, itch is the only symptom. Hillman., *et al.* [8], Considered intrahepatic cholestasis of pregnancy in all women who have itching during pregnancy.

OC can present with severe itching and normal liver/bile acids. Normal serum markers of liver function and/or bile acids at the onset of pruritus do not exclude the later development of OC. There is a need, therefore, to identify early and specific serum marker(s) of OC. Several other disorders were considered to be excluded. For example the absence of hypertension and proteinuria, ALT is a simple bile acid blood test could tell risk of stillbirth [1] Locatelli and colleagues [9] have shown a significantly higher rate of cholestasis in otherwise asymptomatic women seropositive for hepatitis C. In our study all the patients were seronegative for viral hepatitis C and were checked up by the Internist before admission to the study.

It may be extremely stressful for the mother but also carries risks for the baby [6].

Creams, such as aqueous cream with menthol, are safe to use in pregnancy and can provide some relief from itching.

There are some medications, such as ursodeoxycholic acid (UDCA), that help reduce bile acids and ease itching.

#### Complications

Though cholestasis of pregnancy appears to have no serious health risks to the mother, it has been shown to be associated with somewhat increased risks to the fetus. Total serum bile acid concentration is an important laboratory investigation in any woman with itching in the absence of a rash during pregnancy [10]. In obstetric cholestasis, the most common selected liver function tests are total serum bile acids and transaminases particularly ALT [4].

The most concerning complication in ICP is increased rate of fetal death. Clinical studies clearly show that when obstetric cholestasis complicates pregnancies it may lead to premature births in up to 60%, fetal distress in up to 33%, and intrauterine death in up to 2% of patients [6]. One review of over 1,000 reported cases showed a rate of stillbirth and fetal death at delivery to be 10%. Virtually all of the deaths occur at 36 weeks gestational age or more (normal term delivery is at 40 weeks) [3]. It has been associated with a high incidence of stillbirth and perinatal complications. Meconium staining occurred in 45%, spontaneous preterm labour in

Citation: Magda M Helmi. "Prevalence and complication of Intrahepatic Cholestasis of Pregnancy". Acta Scientific Women's Health 1.3 (2019): 02-07.

05

44%, and intrapartum fetal distress in 22%. Of 86 infants two were stillborn and one died soon after birth in a study by Fisk and Storey [5].

In our clinical study it is clearly shown that when obstetric cholestasis complicates pregnancies it lead to premature births in up to 35%, fetal distress in up to 30%, and intrauterine death in up to 1% of patients.

In a study by Kenyon, AP., *et al.* [11] 36% women required caesarean section. In our study 40% women required caesarean section.

The etiology of obstetric cholestasis is undoubtedly multifactor, with genetic, environmental, and hormonal factors having important roles. Although OC remains the commonest liver disease in pregnancy (>60% of all cases after 22 weeks gestation) the etiology of the disease is unknown.

Because of the presence of meconium associated with the stillbirths, it is thought that the meconium itself may cause a decrease in oxygen available to the fetus. In our study the incidence of meconium stained liquor was high (40%0) in pregnancy with obstetric cholestasis. Some authors have thought that the deaths may be related to an increased incidence of postpartum hemorrhage. The cause of fetal death is acute anoxia [6]. Regardless, it is widely accepted that the deaths are due to a sudden episode of decreased oxygen rather than a chronic or long-term deficiency most probably the cause of fetal death is acute anoxia [5].

#### Treatment

There are two primary objectives in treating cholestasis of pregnancy: alleviating the pruritis and ensuring that the child is born safely.

Until the pathophysiology of obstetric cholestasis is understood more clearly, it seems appropriate to offer all women the same policy of active management.

More active management of obstetric cholestasis pregnancies has reduced the associated fetal and prenatal mortality. (More, frequent antenatal visits, at least twice weekly, visiting professional nutritionists as early as we discover the condition).

Regardless of the severity of the abnormality in liver function [11].

# The alternative treatments available are Systemic treatment

Cholestasis often does not respond to medical therapy of any sort. Some reports indicate success with the use of ursodeoxycholic acid (20-30 mg/kg/d), which acts to increase bile formation and antagonizes the effect of hydrophobic bile acids on biological membranes. Phenobarbital (5 mg/kg/d) may also be useful in some cases [12,13].

Anti-Histamines, Dexamethasone, Vitamin K, S-Adenosyl Mmethionine, Cholestyramine [11]. A diet that is rich in carbohydrates and proteins can be substituted for a diet containing long-chain triglycerides., fat-soluble vitamin formulation A, D, E, and K supplementation is safe and potentially effective in patients with cholestasis [12].

#### **Topical treatments**

If the skin is well moisturized, pruritus may be relieved. Despite the use of all of the above medication there was no conclusive evidence of their curative effects.

## Conclusion

Cholestasis of pregnancy appears to have serious health risks to the fetus, It increases the risk of preterm labor, operative, fetal distress and stillbirth. It manifests itself in the second or third trimester of pregnancy with generalized pruritus, most pronounced in palms and soles. It is characterized by increased hepatic enzyme (ALT) Jaundice is relatively uncommon, complicating only the most severe and prolonged episodes. To avoid complication, routine liver function tests should be done for all pregnant patients with itching without a rash.

#### **Summary**

A controlled trial performed at 6th October Health Insurance Unit, to evaluate the incidence of obstetric cholestasis, in the sample examined it was 1.14% pregnant woman cholestasis of pregnancy appears to have serious health risks to the fetus, It increases the risk of preterm labor, operative, fetal distress and stillbirth.. Total serum bile acid concentration increases in pregnant woman with cholestasis of pregnancy. Liver function is getting worse with progress of pregnancy.

## Acknowledgment

The author would like to acknowledge Dr. Rashad, O. the Internist, Dr. Zachariah, Z. the ultrasonographer,

and Dr. El-Arabi, M. and all the members of the 6th October Health Insurance Unite.

#### **Bibliography**

- 1. Williamson C. Consultant Obstetric Physician and Chair in Women's Health at Guy's and St Thomas' and King's College London, PUBLIC RELEASE (2019).
- 2. Brouwers L., *et al.* "Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels". *AJOG* 212.1 (2015): 100.e1-100.e7.
- 3. Wilson B and Haverkamp A. "Cholestatic jaundice of pregnancy: new perspectives". *Obstetrics and Gynecology* 54 (1979): 650-652.
- 4. Laatikainen and Ikonen E. "Serum bile acids in cholestasis of pregnancy". *Obstetrics and Gynaecology* 50 (1977): 318-313.
- Fisk NM and Storey GN. "Fetal outcome in obstetric cholestasis". *British Journal of Obstetrics and Gynaecology* 95.11 (1988): 1137-1143.
- Milkiewicz P., *et al.* "Obstetric cholestasis". *BMJ* 324 (2002): 123-124.
- Reyes H and Sjovall J. "Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy". *Annals of Medicine* 32 (2000): 94.
- 8. Hillman C., *et al.* "Intrahepatic cholestasis of pregnancy". *BMJ* (2016): 353.
- 9. Locatelli A., *et al.* "Hepatitis C virus infection is associated with a higher incidence of cholestasis of pregnancy". *British Journal of Obstetrics and Gynaecology* 106 (1999): 498.
- 10. AL Walker., *et al.* "Role of bile acid measurement in pregnancy". *Annals of Clinical Biochemistry* 39.2 (2002): 105-113.
- 11. Kenyon AP., *et al.* "Obstetric cholestasis". in Progress in Obstet and Gynaecol. ed. John Studd (2005).

- 12. Vijaya Benerji G and Vijaya Benerji G. "Comparative Study of ALT, AST, GGT and Uric Acid Levels in Liver Diseases". *IOSR Journal of Dental and Medical Sciences* 7.5 (2013): 72-75.
- Kilby MD and Barber KJ. "Management of abnormal liver function in pregnancy". In: Recent advances in obstetrics and gynecology (22). Ed: John Bonnar and William Dunlop. (2003).

## Volume 1 Issue 3 August 2019

## © All rights are reserved by Magda M Helmi.